Novartis
NVS
NVS
1,200 hedge funds and large institutions have $14.9B invested in Novartis in 2023 Q2 according to their latest regulatory filings, with 98 funds opening new positions, 341 increasing their positions, 476 reducing their positions, and 68 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
1,200
Holders Change
+20
Holders Change %
+1.69%
% of All Funds
18.92%
Holding in Top 10
13
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-7.14%
% of All Funds
0.21%
New
98
Increased
341
Reduced
476
Closed
68
Calls
$677M
Puts
$292M
Net Calls
+$384M
Net Calls Change
+$46.3M
Top Buyers
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$67.9M |
| 2 |
Morgan Stanley
New York
|
+$65.7M |
| 3 |
CCMG
Clark Capital Management Group
Philadelphia,
Pennsylvania
|
+$39.7M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$33.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$26.7M |
Top Sellers
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$716M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$394M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$263M |
| 4 |
Goldman Sachs
New York
|
-$176M |
| 5 |
Primecap Management
Pasadena,
California
|
-$143M |
